Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teladoc (TDOC – Research Report), Gilead Sciences (GILD – Research Report) and Sanofi (SNYNF – Research Report).
Gilead Sciences (GILD)
In a report issued on April 26, Daina Graybosch from Leerink Partners maintained a Hold rating on Gilead Sciences, with a price target of $76.00. The company’s shares closed last Monday at $65.94, close to its 52-week low of $64.63.
According to TipRanks.com, Graybosch has 0 stars on 0-5 stars ranking scale with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $82.95, implying a 27.0% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Hold rating on the stock with a $82.00 price target.
Sanofi (SNYNF)
In a report issued on April 25, David Risinger from Leerink Partners reiterated a Buy rating on Sanofi, with a price target of EUR100.00. The company’s shares closed last Thursday at $95.54.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $112.79, representing a 18.1% upside. In a report issued on April 22, UBS also maintained a Buy rating on the stock with a EUR110.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TDOC:
